Puma Biotechnology | PBYI - Beneficio Operativo





Beneficio Operativo Cambio Fecha
Agios Pharmaceuticals USD -110.02M 11.55M 2026-03
Alnylam Pharmaceuticals USD 137.59M 108.19M 2026-03
Amgen USD 3.83B 130M 2026-03
Biogen USD 514.3M 128.8M 2026-03
BioMarin Pharmaceutical USD 129.65M 68.74M 2026-03
Daiichi Sankyo JPY 89.54B 42.01B 2025-12
Esperion Therapeutics USD 85.23M 95.19M 2025-12
Exelixis USD 251.34M 15.43M 2026-03
Gilead Sciences USD 2.68B 284M 2026-03
Glaxosmithkline GBP 2.3B 1.46B 2025-12
Incyte USD 324.17M 59.7M 2026-03
MacroGenics USD -12.1M 30.74M 2025-12
Moderna USD -1.39B 531M 2026-03
Novartis USD 4.24B 171M 2026-03
Pfizer USD 4.99B 340M 2026-03
PTC Therapeutics USD 45.89M 127.51M 2026-03
Puma Biotechnology USD 22.08M 24.26M 2024-09
Regeneron Pharmaceuticals USD 744.8M 153.8M 2026-03
Roche Holding CHF 9.56B 3.8B 2025-12
Sangamo BioSciences USD -33.51M 12.77M 2024-06
Sarepta Therapeutics USD 358.43M 768.52M 2026-03
Takeda JPY -13.62B 182.44B 2026-03
TG Therapeutics USD 34.8M 15.7M 2026-03
Ultragenyx Pharmaceutical USD -216M 102M 2026-03
Vanda Pharmaceuticals USD -40.66M 29.66M 2024-12
Vertex Pharmaceuticals USD 1.14B 124.5M 2026-03